SCHEMBL5877418

SCHEMBL5877418

Cc1ccc(S(=O)(=O)n2nc(NC3CCC3)c3c2CC(c2ccccc2)(c2cccnc2)C=C3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GBA1 P04062 3/20 0.33
CCR6 P51684 1/20 0.32
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
NAMPT P43490 2/20 0.31
NOD2 Q9HC29 1/20 0.31
NOD1 Q9Y239 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876940 0.98 CYP3A4 (0.35) ALDH1A1CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL5877112 0.97 ALDH1A1 (0.37) ALDH1A1CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL5877529 0.94 CYP3A4 (0.36) ALDH1A1CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL5876198 0.93 USP2 (0.37) ALDH1A1CYP2C19USP2MAPK1LMNA
SCHEMBL5876674 0.93 USP2 (0.35) ALDH1A1CYP2C19USP2MAPK1GBA1
SCHEMBL5876012 0.90 NR1H2 (0.36) ALDH1A1CYP2C19USP2MAPK1CCR6
SCHEMBL5876220 0.89 NR1H2 (0.34) ALDH1A1CYP2C19USP2MAPK1LMNA
SCHEMBL5877652 0.89 ACHE (0.34) ALDH1A1CYP3A4USP2MAPK1LMNA
SCHEMBL5876201 0.89 USP2 (0.34) ALDH1A1USP2MAPK1LMNASMN1; SMN2
SCHEMBL5878323 0.87 HTR6 (0.33) ALDH1A1USP2MAPK1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT ALDH1A1 166/4885CYP3A4 26/4885CYP2C19 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.